For home parenteral nutrition, PICCs should be used for short-term therapy
the ONA take:
According to a new study published in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at Aalborg University in Aalborg, Denmark, have found that using a peripherally inserted central venous catheter (PICC) for one additional infusion day per week significantly reduced the amount of time before a first bloodstream infection.
For the study, researchers sought to examine whether environmental factors have an influence on the amount of time before a first infection in home parenteral nutrition patients.
Researchers enrolled 136 patients suffering from intestinal failure who were receiving home parenteral nutrition. There was a total of 169 tunneled vascular access devices and 126 PICCs used.
Researchers also found that using a tunneled vascular access device managed by a home care nurse increased the incidence of bloodstream infections.
The authors conclude that the PICCs should only be used for short-term therapy and when few infusion days per week are necessary.
Using a peripherally inserted central venous catheter significantly reduced the amount of time before a first bloodstream infection.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|